Dr. Allison Rosenthal talks about her leukemia survivorship journey and how she advocates for AYA patients with cancer. In vivo T-cell depletion with antithymocyte/antilymphocyte globulin prior to HSCT is effective at reducing GVHD. Treating myelofibrosis patients with ruxolitinib before, during, and after HSCT is safe and effective. Persistence of cells with MF-associated driver mutations following allogeneic HSCT was linked to outcomes. Ropeginterferon alfa-2b is an effective treatment for patients with primary myelofibrosis in the pre-/early fibrotic stage. Hemoglobin and platelets are associated with overall survival in patients with myelofibrosis following allogeneic HSCT. Treatment-naïve myelofibrosis patients who received navitoclax plus ruxolitinib saw a significant reduction in spleen ... The Fellow on Call group discusses the fundamentals of chemotherapy, including basic terminology, optimal dosing, and more. For patients with breast cancer, a regimen of epirubicin followed by adjuvant chemotherapy is associated with worse QOL. Drs. Chadi Nabhan and Jennifer Mack discuss the delicate art of delivering bad news to patients with cancer. Moshe Chasky and Allen Lord Terzian, of Alliance Cancer Specialists, join Dr. Chadi Nabhan to discuss a high-stakes lawsuit. Drs. Vishwas Paralkar and Sophia Gayle discuss CBX-15, a novel therapy for triple-negative breast cancer. The group discusses chimeric antigen receptor T-cell therapy, bispecific T-cell engagers, and autologous transplants. The Fellow on Call team discusses the management of advanced-stage DLBCL, including the role of CNS prophylaxis and more. The Fellow on Call group discusses the early management of diffuse large B-cell lymphoma. Dr. Patel joins The Oncology Brothers to discuss in-depth how to treat cutaneous melanoma using a treatment algorithm. A cardio-oncology rehabilitation program can benefit cancer survivors at high risk of cardiovascular disease. Nonmelanoma skin cancer is responsible for more deaths worldwide than melanoma, the more serious form of skin cancer. Shelly Rosenfeld discusses the intersection between medical and legal concerns in cancer care. Dan Forche, CEO of PreludeDx, a leader in precision medicine for early-stage breast cancer, discusses DCISionRT.